LJP 394: Began a Phase I dose-escalation trial

La Jolla Pharmaceutical Co. (LJPC), San Diego Product: LJP 394, which uses the company's tolerance technology to prevent B cells from producing anti-DNA antibodies Indication: Lupus Status: Began a Ph...